Tenpoint Therapeutics Launches With $70 Million Series A Financing To Reverse Vision Loss Through Engineered Cell-Based Therapeutics And In Vivo Reprogramming
Tenpoint Therapeutics Launches With $70 Million Series A Financing To Reverse Vision Loss Through Engineered Cell-Based Therapeutics And In Vivo Reprogramming
07/12/23, 11:18 AM
Location
seattleMoney raised
$70 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
F Prime, Ucl Technology Fund, Eight Roads, Qiming Venture Partners Usa, Sofinnova Partners, F Prime Capital, British Patient Capital
Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases, today announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. The Series A round included new investment from British Patient Capital as well as funding from all seed investors including F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund among others. F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
Company Info
Location
seattle, washington, united states
Additional Info
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision. Tenpoint’s global team is united by our passion for science and our commitment to patients.